Biodexa Pharmaceuticals Plc ADR (BDRX)

$1.45 -0.18 (-11.04%)
Market Cap 1.10M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 3,769,300
Avg Vol 1,298,032
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 4%
Beta 0.95
Analysts Strong Buy
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
thatboytrades
thatboytrades Feb. 5 at 12:15 AM
$BDRX looks like everyone is breaking even when this thing goes
0 · Reply
fisher04
fisher04 Feb. 4 at 11:08 PM
$BDRX i am down big in this shit . average is above 2$ holding have no choice but not adding.
0 · Reply
thatboytrades
thatboytrades Feb. 4 at 9:31 PM
$BDRX i need 60% rally to breakeven.
1 · Reply
Lehameri
Lehameri Feb. 4 at 8:56 PM
$BDRX after some repositioning since near end of 2020, still have a few shares left. Its still something no matter how small. This nuwe pstv rfl glbs apvo could all benefit from explosives moves that they are surely been absent of.
1 · Reply
MCapitalJ
MCapitalJ Feb. 4 at 8:29 PM
$KIDZ $BDRX 👀
1 · Reply
SqueezzChamber
SqueezzChamber Feb. 4 at 6:25 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ limited spots $IBRX $BDRX $HSAI $SKYT .
0 · Reply
jsmith14
jsmith14 Feb. 4 at 5:16 PM
$BDRX makes sense!
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 4 at 5:10 PM
$BDRX you'd think that with such an impressive bd opportunity, they would've been able to also secure a financing to conduct the trial. i'm perplexed.
0 · Reply
LFC4EVER
LFC4EVER Feb. 4 at 3:47 PM
$BDRX In with a starter... GLTA 🍺
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 4 at 3:35 PM
$BDRX lets not chase a ticker that has 50 424b
1 · Reply
Latest News on BDRX
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 6 weeks ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 2 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 2 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 3 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 4 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 5 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 5 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 6 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 6 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 6 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 7 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 7 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 7 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 8 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 8 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 8 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 8 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 9 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 9 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 9 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 10 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 10 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 11 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 11 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

thatboytrades
thatboytrades Feb. 5 at 12:15 AM
$BDRX looks like everyone is breaking even when this thing goes
0 · Reply
fisher04
fisher04 Feb. 4 at 11:08 PM
$BDRX i am down big in this shit . average is above 2$ holding have no choice but not adding.
0 · Reply
thatboytrades
thatboytrades Feb. 4 at 9:31 PM
$BDRX i need 60% rally to breakeven.
1 · Reply
Lehameri
Lehameri Feb. 4 at 8:56 PM
$BDRX after some repositioning since near end of 2020, still have a few shares left. Its still something no matter how small. This nuwe pstv rfl glbs apvo could all benefit from explosives moves that they are surely been absent of.
1 · Reply
MCapitalJ
MCapitalJ Feb. 4 at 8:29 PM
$KIDZ $BDRX 👀
1 · Reply
SqueezzChamber
SqueezzChamber Feb. 4 at 6:25 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ limited spots $IBRX $BDRX $HSAI $SKYT .
0 · Reply
jsmith14
jsmith14 Feb. 4 at 5:16 PM
$BDRX makes sense!
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 4 at 5:10 PM
$BDRX you'd think that with such an impressive bd opportunity, they would've been able to also secure a financing to conduct the trial. i'm perplexed.
0 · Reply
LFC4EVER
LFC4EVER Feb. 4 at 3:47 PM
$BDRX In with a starter... GLTA 🍺
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 4 at 3:35 PM
$BDRX lets not chase a ticker that has 50 424b
1 · Reply
BaridBanger
BaridBanger Feb. 4 at 2:50 PM
$BDRX back in
0 · Reply
lifeisgood28
lifeisgood28 Feb. 4 at 2:44 PM
$BDRX well news didnt do anything..
1 · Reply
ScoobieDo
ScoobieDo Feb. 4 at 2:36 PM
$BDRX $1 incoming.!!!!!!!!
1 · Reply
timelesstrades
timelesstrades Feb. 4 at 2:26 PM
$BDRX not sure when people will realize that the company they are making deals with are in this league
0 · Reply
timelesstrades
timelesstrades Feb. 4 at 2:22 PM
$BDRX I’m hearing you
0 · Reply
Tom678
Tom678 Feb. 4 at 2:15 PM
$BDRX Otsuka pharmaceuticals is a multi billion dollar giant company. This provides massive credibility
0 · Reply
timelesstrades
timelesstrades Feb. 4 at 2:11 PM
$BDRX this is great news!
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 4 at 2:05 PM
$BDRX gets news. Gets volume. But its not what you think
1 · Reply
Tom678
Tom678 Feb. 4 at 2:01 PM
$BDRX with this killer news it’s trying to manipulate stock so people sell , not happening here
0 · Reply
useles
useles Feb. 4 at 2:01 PM
$BDRX this dump is 100% dilution.
0 · Reply
StockGuru95
StockGuru95 Feb. 4 at 2:00 PM
$BDRX with a licensing news! Fun to watch 👀
1 · Reply
premarketmaker
premarketmaker Feb. 4 at 1:59 PM
$BDRX $1.51 /hard stops - this is all time low
0 · Reply